A trial participant in remission criticizes saline placebos for cancer patients

A trial participant says they are in remission and enrolled in a three-year, 50/50 blinded placebo trial. They want the drug but also want to advance science, crediting women in the previous generation for doing the same to help them. Being in remission makes the stakes feel tolerable, they say. Still, they argue that “no cancer patient should get saline” and express hope that embracing AI in biology could help many people.